Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• OASIS 4 trial showed approximately 13-14% average weight loss over 64 weeks with oral Wegovy, with up to 16.6% among adherent participants

  80% confidence

• STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks with Wegovy injection

  80% confidence

• Compounded semaglutide in multi-dose vials can create dosing confusion, especially when instructions use 'units' rather than mg/mL measurements, leading to overdoses in some reported cases

  80% confidence

• Limited-time savings offer for oral Wegovy starting dose at approximately $149 per month

  80% confidence

• FDA is not aware of a basis for compounding using salt forms such as semaglutide sodium or semaglutide acetate

  80% confidence

• Limited-time cash-pay savings offer for Wegovy injection at $199 for initial doses, then $349 thereafter

  80% confidence

• Novo Nordisk plans a full U.S. launch of oral Wegovy in early January 2026

  80% confidence

• MEDVi does not provide any Healthcare Services through the Platform and is not licensed to practice medicine

  80% confidence

• The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed

  80% confidence

• FDA received reports of adverse events including hospitalizations that may be related to dosing errors with compounded semaglutide products

  80% confidence

• MEDVi-affiliated medical professional entities are not contracted healthcare providers with any health insurance plans

  80% confidence

• Payment does not guarantee the writing or dispensing of a prescription

  80% confidence